• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

byMinjee Kim
June 29, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In idiopathic pulmonary fibrosis (IPF) patients, phosphodiesterase 4 inhibitor BI 1015550 prevented decline in lung function compared to a placebo.

2. Incidence of adverse events, consisting mostly of gastrointestinal disorders, was higher in the BI 1015550 group compared to the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Currently approved antifibrotic medications, such as nintedanib and pirfenidone, are unable to completely prevent the progression of fibrosis in patients with IPF. Progression of fibrosis in this population can have a devastating impact on prognosis as well as quality of life. This phase two randomized control trial evaluated the efficacy and safety of BI 1015550 as compared to placebo control. BI 1015550 is an oral preferential inhibitor of phosphodiesterase 4 enzyme, a key driver of IPF progression. Each group received two daily doses of the drug or placebo for 12 weeks. Patients were followed for one week after completion of the regimen. Regardless of the presence or absence of concomitant antifibrotic agents, lung function, as measured by forced vital capacity, decreased in the placebo group, while remaining stable in the BI 1015550 group. The study group reported a higher percentage of patients with adverse events, several of which led to the discontinuation of BI 1015550. The most common adverse events were diarrhea and fatigue. The limitations of this study include the small sample size and short treatment regimen and follow-up duration, which limited the generalizability of the results.

Click to read the study in NEJM

Relevant Reading: Idiopathic Pulmonary Fibrosis

RELATED REPORTS

Exposure to particulate matter 2.5 ÎĽm or less associated with adverse outcomes among patients with fibrotic interstitial lung disease

Roflumilast cream superior to vehicle cream in the treatment of plaque psoriasis – the DERMIS-1 and DERMIS-2 trials

Racial differences exist in emphysema prevalence in adults with normal spirometry findings

In-Depth [randomized controlled trial]: In the present study, IPF patients over the age of 40 with (n=74) and without (n=73) background antifibrotic use were randomly assigned to receive BI 1015550 or placebo treatment in a 2:1 ratio. Patients received two daily doses of the drug or placebo for 12 weeks and were followed up for one week after completion. The study used the Bayesian and mixed model with repeated measures (MMRM) approaches to conduct analysis. Both the Bayesian and MMRM approaches demonstrated a more significant decline in forced vital capacity (FVC) in the placebo group compared to BI 1015550 group. In the more conservative Bayesian analysis, the median change in FVC from baseline to week 12 in the BI 1015550 and placebo groups was 5.7mL (credible interval, -39.1 to 50.1) and -81.7mL (95% credible interval, -133.5 to -44.8) respectively among patients without concomitant antifibrotic use, and 2.7mL (95% credible interval, -32.8 to 38.2) and -59.2mL (95% credible interval, -111.8 to -17.9) respectively among patients with concomitant antifibrotic use. There was a higher incidence of adverse events in the BI 1015550 group compared to the placebo for both patients with (65% and 52% for BI 1015550 and placebo groups respectively) and without (73% and 68% for BI 1015550 and placebo groups respectively) concomitant antifibrotic use. Adverse events for 13 patients led to the discontinuation of BI 1015550. No patients discontinued the placebo. Diarrhea was the most common adverse event. Future phase three trials in larger study cohorts are necessary to support the therapeutic effects and safety of BI 1015550 for IPF.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antifibrotic therapyBI 1015550forced vital capacityFVCidiopathic pulmonary fibrosisIPFlung functionPDE4PDE4 inhibitorPFPFTphosphodiesterase 4 inhibitorpulmonary fibrosis
Previous Post

Post-operative opioids at discharge increase adverse events without improving pain management

Next Post

United States medical cannabis registration increased significantly between 2016 and 2020

RelatedReports

Lessons from real-world implementation of lung cancer screening
Chronic Disease

Exposure to particulate matter 2.5 ÎĽm or less associated with adverse outcomes among patients with fibrotic interstitial lung disease

October 27, 2022
Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)
Chronic Disease

Roflumilast cream superior to vehicle cream in the treatment of plaque psoriasis – the DERMIS-1 and DERMIS-2 trials

September 24, 2022
Non-invasive ventilation linked with lower mortality in COPD exacerbations
Chronic Disease

Racial differences exist in emphysema prevalence in adults with normal spirometry findings

August 10, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

INPULSIS: Nintedanib for Idiopathic Pulmonary Fibrosis [Classics Series]

June 16, 2022
Next Post
Parental cannabis use increasing, cigarette use decreasing

United States medical cannabis registration increased significantly between 2016 and 2020

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options